MedTrace Logo

Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy

NCT03463161 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2020-01-27

Study results available
· View outcomes & findings →

Summary

Study to determine response rate of the combination of pembrolizumab plus epacadostat in patients with head and neck cancers that have received prior immunotherapy.

Conditions

Interventions

DRUG

Pembrolizumab

Pembrolizumab (200mg/kg) given by intravenous infusion every 3 weeks.

DRUG

Epacadostat

Epacadostat (100mg) taken by mouth twice a day.

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Tanguy Seiwert, MD · University of Chicago

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-23
Primary Completion
2018-12-04
Completion
2018-12-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03463161 on ClinicalTrials.gov